Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Navigating choice in multiple sclerosis management
Neurological Research and Practice Open Access 28 February 2019
-
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
BMC Neurology Open Access 19 July 2016
-
Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
BMC Neurology Open Access 16 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Klotz, L., Meuth, S. G. & Wiendl, H. Immune mechanisms of new therapeutic strategies in multiple sclerosis—a focus on alemtuzumab. Clin. Immunol. 142, 25–30 (2012).
CAMMS223 Trial Investigators. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).
Cohen, J. A. et al. Alemtuzumab versus interferon β-1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).
Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).
Jones, J. L. et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052–2061 (2009).
Thompson, S. A., Coles, A. J. & Jones, J. L. Peripheral expansion dominates early T cell reconstitution following alemtuzumab treatment of multiple sclerosis—implications for secondary autoimmunity [abstract P457]. Mult. Scler. 17 (10 Suppl.), S191–S192 (2011).
Jones, J. L., Compston, D. A. & Coles, A. J. Predicting autoimmunity following treatment of multiple sclerosis with alemtuzumab [abstract P1009]. Mult. Scler. 17 (10 Suppl.), S459 (2011).
Coles, A. J. et al. Alemtuzumab versus interferon β-1a in early relapsing–remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 10, 338–348 (2011).
Walsh, M., Chaudry, A. & Jayne, D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322–1327 (2008).
Coles, A. J. et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78, 1069–1078 (2012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
H. Wiendl has received honoraria for lecturing, council and advisory boards, and travel expenses for attending meetings from Bayer Health Care, Biogen Idec/Elan Corporation, CSL Behring, Fresenius, Lilly, Lundbeck, Merck Serono, Novartis, Genzyme/Sanofi Aventis, and TEVA. He has served or serves as a consultant for Biogen Idec, Genzyme/Sanofi-Aventis, Merck Serono, Novartis Pharma, and NovoNordisk, and receives research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Fresenius, Genzyme/Sanofi, Merck Serono, Novartis, Novo Nordisk, and TEVA. B. Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, CSL Behring, Genzyme/Sanofi Aventis, Grifols, Merck Serono, Novartis, Roche, Sanofi Aventis, Talecris, and TEVA Neurosciences.
Supplementary information
Supplementary Figure 1
Four types of immunotherapeutic approaches and their effect on the immunopathogenesis of multiple sclerosis. (PDF 251 kb)
Rights and permissions
About this article
Cite this article
Wiendl, H., Kieseier, B. Reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol 9, 125–126 (2013). https://doi.org/10.1038/nrneurol.2013.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.2
This article is cited by
-
Comparison of the antibacterial activity of Australian Terminalia spp. extracts against Klebsiella pneumoniae: a potential treatment for ankylosing spondylitis
Inflammopharmacology (2022)
-
CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
Mucosal Immunology (2021)
-
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
Nature Reviews Neurology (2020)
-
Navigating choice in multiple sclerosis management
Neurological Research and Practice (2019)
-
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
BMC Neurology (2016)
